Investment View: Hold on to Astra as new chief cuts costs to do deals

If Mr Soriot does get it right the pay off could be very big. But keep a close watch on developments

It doesn't seem, on the face of it, like the smartest strategic move. You're a drug company, many of your most profitable treatments are coming off patent, the mooted replacements haven't produced, so you sack a load of R&D staff. Hmm.

The job cuts that Pascal Soriot has imposed at AstraZeneca seem so clichéd. A new chief executive arrives and tries to impress the City with what a tough guy he is by cutting costs, which these days means jobs.

Not everyone was impressed, although the overall reaction to Mr Soriot's strategy was favourable, at least in terms of the share price, which finished ahead.

Here's the method in the madness. What Astra is doing is sharpening its focus, concentrating on what Mr Soriot feels are the best bets.

From here on, Astra will concentrate on respiratory illness, inflammation and autoimmune diseases, cardiovascular and metabolic illnesses, and cancer.

There will also be a secondary focus on infection and vaccines and neuroscience, although Mr Soriot says investments in these areas will be more "opportunity-driven".

Thing is, while Astra's is streamlining, other drug giants have gone the other route, diversifying in an attempt to reduce some of the pressure on their research engines.

Still, let's look at one of the opportunities that Astra is hoping will be a winner. Moderna Therapeutics, a small biotech firm based in Cambridge, Massachusetts, uses synthetic messenger RNA to tell a patient's cells to produce various desired proteins. It's a potential alternative to gene therapy and could, in theory, persuade a cell to produce any therapeutic protein you could desire, which could be useful in treating a huge range of conditions.

Astra gets first dibs (for a five-year period) on drugs using Moderna's technology to treat cardiovascular and metabolic diseases, plus some exclusive rights for cancer treatments. It is paying $240m (£158m) up front, and Moderna could make a further $180m down the line.

This is one of the largest partnership deals ever seen between a drug giant and a biotech that has yet to bring a treatment to clinical trials. Astra is betting big on it coming off.

Astra itself represents something of a bet for investors.

From a financial standpoint, the three sets of job cuts that have been announced recently – and more than 11,000 posts have gone in just over a year – will cost the company $2.3bn in one-off restructuring charges but save an annual $800m thereafter.

Well, that should provide further fuel for spending on deals, and Astra might need them if it continues to struggle with its own drugs.

The shares are not all that expensive, trading at 8.8 times this year's forecast earnings. That rises to 9.1 times next year's forecasts.

Plans for a share buyback have been cancelled to give more flexibility for doing deals, but the dividend is nearly twice covered by earnings, and analysts think it is stable. The forecast yield is a more than respectable 5.8 per cent.

In October I advised holding Astra at 2,896.5p. You'll be happy if you did. It is probably just about worth staying in there, for that yield if nothing else. If Mr Soriot does get it right the pay-off could be very big. But keep a close watch on developments.

If you want drugs, I'd stick to GlaxoSmithKline, which is far less reliant on blockbuster treatments (thanks to that diversification). I said keep buying at 1,406.5p in October, and made the shares among our 10 to follow after they had eased back to 1,335p by 31 December (I'll update on the 10 over Easter). The shares have since jumped, and rightly so.

Even so, at just 13 times this year's forecast earnings, falling to 12 times next year, with a 5.2 per cent yield rising to 5.5 per cent, it is a more attractive and less risky buy than Astra. I'd still rate the company as a buy even now.

Another share on its downers but worth buying, from a completely different sector, is Bloomsbury, the publisher of Harry Potter fame. The boy wizard might be enjoying his retirement, with the film franchise also finished, but the company is more than coping.

Today it said it will meet forecasts in both digital and print books for the year, and at only eight times next year's earnings (for the year ending 28 February 2014) while offering a forecast yield of over 5 per cent, buy to put a bit of magic in your portfolio.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksA special investigation by Andy McSmith
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: HR Benefits Manager

£40000 - £50000 per annum + pro rata: SThree: SThree Group have been well esta...

Recruitment Genius: Office Manager / Financial Services

£30000 - £37000 per annum: Recruitment Genius: Established in 1999, a highly r...

Jemma Gent: Year End Accountant

£250-£300 Day Rate: Jemma Gent: Are you a qualified accountant with strong exp...

Jemma Gent: Management Accountant

£230 - £260 Day Rate: Jemma Gent: Do you want to stamp your footprint in histo...

Day In a Page

War with Isis: Fears that the looming battle for Mosul will unleash 'a million refugees'

The battle for Mosul will unleash 'a million refugees'

Aid agencies prepare for vast exodus following planned Iraqi offensive against the Isis-held city, reports Patrick Cockburn
Yvette Cooper: We can't lose the election. There's too much on the line

Yvette Cooper: We can't lose the election. There's too much on the line

The shadow Home Secretary on fighting radical Islam, protecting children, and why anyone in Labour who's thinking beyond May must 'sort themselves out'
A bad week for the Greens: Leader Natalie Bennett's 'car crash' radio interview is followed by Brighton council's failure to set a budget due to infighting

It's not easy being Green

After a bad week in which its leader had a public meltdown and its only city council couldn't agree on a budget vote, what next for the alternative party? It's over to Caroline Lucas to find out
Gorillas nearly missed: BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter

Gorillas nearly missed

BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter
Downton Abbey effect sees impoverished Italian nobles inspired to open their doors to paying guests for up to €650 a night

The Downton Abbey effect

Impoverished Italian nobles are opening their doors to paying guests, inspired by the TV drama
China's wild panda numbers have increased by 17% since 2003, new census reveals

China's wild panda numbers on the up

New census reveals 17% since 2003
Barbara Woodward: Britain's first female ambassador to China intends to forge strong links with the growing economic superpower

Our woman in Beijing builds a new relationship

Britain's first female ambassador to China intends to forge strong links with growing economic power
Courage is rare. True humility is even rarer. But the only British soldier to be awarded the Victoria Cross in Afghanistan has both

Courage is rare. True humility is even rarer

Beware of imitations, but the words of the soldier awarded the Victoria Cross were the real thing, says DJ Taylor
Alexander McQueen: The catwalk was a stage for the designer's astonishing and troubling vision

Alexander McQueen's astonishing vision

Ahead of a major retrospective, Alexander Fury talks to the collaborators who helped create the late designer's notorious spectacle
New BBC series savours half a century of food in Britain, from Vesta curries to nouvelle cuisine

Dinner through the decades

A new BBC series challenged Brandon Robshaw and his family to eat their way from the 1950s to the 1990s
Philippa Perry interview: The psychotherapist on McDonald's, fancy specs and meeting Grayson Perry on an evening course

Philippa Perry interview

The psychotherapist on McDonald's, fancy specs and meeting Grayson Perry on an evening course
Bill Granger recipes: Our chef recreates the exoticism of the Indonesian stir-fry

Bill Granger's Indonesian stir-fry recipes

Our chef was inspired by the south-east Asian cuisine he encountered as a teenager
Chelsea vs Tottenham: Harry Kane was at Wembley to see Spurs beat the Blues and win the Capital One Cup - now he's their great hope

Harry Kane interview

The striker was at Wembley to see Spurs beat the Blues and win the Capital One Cup - now he's their great hope
The Last Word: For the good of the game: why on earth don’t we leave Fifa?

Michael Calvin's Last Word

For the good of the game: why on earth don’t we leave Fifa?
HIV pill: Scientists hail discovery of 'game-changer' that cuts the risk of infection among gay men by 86%

Scientists hail daily pill that protects against HIV infection

Breakthrough in battle against global scourge – but will the NHS pay for it?